"Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice

S. Tereshchenko, N. Smirnov, S. Bychkovskaya, S. Buynova, T. Golosova (Krasnoyarsk, Russian Federation)

Source: Annual Congress 2006 - Therapy in childhood asthma II
Session: Therapy in childhood asthma II
Session type: Thematic Poster Session
Number: 4099
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Tereshchenko, N. Smirnov, S. Bychkovskaya, S. Buynova, T. Golosova (Krasnoyarsk, Russian Federation). "Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice. Eur Respir J 2006; 28: Suppl. 50, 4099

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects.
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily (OD) efficacy in asthma when dosed in the evening
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 457s
Year: 2007

Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo
Source: Eur Respir J 2001; 18: Suppl. 33, 123s
Year: 2001

Low-dose (100 μg, b.i.d.) inhaled fluticasone propionate (FP) is as effective as high-dose (500 μg, b.i.d.) in mild symptomatic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 96s
Year: 2001

Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003

Low dose inhaled fluticasone propionate compared with montelukast in children 6-12 years old
Source: Eur Respir J 2003; 22: Suppl. 45, 535s
Year: 2003

Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 44s
Year: 2004

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004